Chief Executive Officer
Shaun Thaxter is Chief Executive Officer bringing to Indivior more than 25 years of global and U.S. specialty pharmaceutical industry experience and a deep understanding of addiction as a chronic disease, and the people it affects. Working in partnership with other addiction thought-leaders and stakeholders, Indivior is committed to broadening awareness that addiction is a complex and chronic disease; enhancing scientific understanding of the disease and patient’s unmet needs; and investing in innovation to develop life-transforming treatment options for people suffering from addiction.
In 2003, with a focus on shifting societal attitudes towards addiction and expanding access to quality treatment options, Shaun led the commercialization of buprenorphine-based treatment, establishing the U.S. Suboxone portfolio. In late 2014, when Reckitt Benckiser Pharmaceuticals became an independent public company, now known as Indivior, Shaun was appointed as Chief Executive Officer. Since then, Indivior has created a sustainable growth model by placing patients firmly at the heart of its business and progressed towards its vision that all patients around the world have access to quality treatment for the chronic condition and co-occurring disorders of addiction.